Specialty Pharma Journal Specialty, Precision & Technology
NICE has today recommended ataluren (Translarna, PTC Therapeutics) for treating children aged 5 and over with Duchenne muscular dystrophy (DMD) caused by a nonsense mutation. The drug has been called a ‘step change’ in the management of the disease which causes progressive muscle wasting and is usually fatal by age …
Tag Archives: NICE
April, 2016
February, 2015
-
25 February
NICE Recommends Use of Pfizer’s Inlyta in Kidney Cancer and Rejects Dendreon’s Provenge for Prostate Cancer
The National Institute for Health and Care Excellence (NICE) issued two final guidelines, recommending Pfizer’s Inlyta (axitinib) in kidney cancer, but rejecting Dendreon’s Provenge (sipuleucel-T) in prostate cancer. In guidance issued to the NHS, the drug pricing watchdog recommended Inlyta as a second-line option for treating adults with advanced renal …
-
13 February
In Final Draft Guidance NICE Rejects Celgene’s Multiple Myeloma Drug
England’s cost-regulator issued a final draft guidance rejecting Celgene’s next generation multiple myeloma drug, due to its high cost. In the National Institute for Health and Care Excellence (NICE) final draft guidance, it recommended against use of Celgene’s Imnovid (pomalidomide) for treatment of patients with multiple myeloma, a type of …